Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and
represents a high-grade neoplasm of skeletal myoblast-like cells. Decades of clinical and …

The spectrum of tumours arising in childhood is fundamentally different from that seen in
adults, and they are known to be divergent from adult malignancies in terms of cellular …

Abstract The Zero Childhood Cancer Program is a precision medicine program to benefit
children with poor-outcome, rare, relapsed or refractory cancer. Using tumor and germline …

Genomic studies of pediatric cancer have primarily focused on specific tumor types or high-
risk disease. Here, we used a three-platform sequencing approach, including whole …

PURPOSE The National Cancer Institute–Children's Oncology Group Pediatric MATCH trial
aimed to facilitate evaluation of molecular-targeted therapies in biomarker-selected cohorts …

INFORM is a prospective, multinational registry gathering clinical and molecular data of
relapsed, progressive, or high-risk pediatric patients with cancer. This report describes long …

Although significant improvements have been made in the outcomes of children with cancer,
the pace of improvement has slowed in recent years as the limits of therapy intensification …

Neuroblastoma (NB) is the most common and deadly solid tumour in children. Despite the
development of new treatment options for high-risk NB, over half of patients relapse and five …

Purpose Recent years have seen a change in the way that clinical trials are being
conducted. There has been a rise of designs more flexible than traditional adaptive and …

Rapid evaluation and subsequent regulatory approval of new drugs are critical to improving
survival and reducing long-term side-effects for children and adolescents with cancer. The …